Joseph Zasik, DO
Critical Care Medicine · Tyler, TXNPI 1255380028
Payments from drug & device makers
Across 152 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$780
- GSK$689
- Boehringer Ingelheim$308
- United Therapeutics Corporation$173
- Sanofi$133
- Sunovion Pharmaceuticals Inc.$123
- plus $655 from 17 others
What the payments were for
- Food & beverage$2,78997%
- Education$733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $780 |
| GSK | 56 | $689 |
| Boehringer Ingelheim | 15 | $308 |
| United Therapeutics Corporation | 7 | $173 |
| Sanofi | 5 | $133 |
| Sunovion Pharmaceuticals Inc. | 9 | $123 |
| Mylan Specialty L.p. | 7 | $100 |
| Inogen, Inc. | 8 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $71 |
| Grifols USA, LLC | 3 | $62 |
| Genentech USA, Inc. | 3 | $58 |
| Mallinckrodt Enterprises LLC | 3 | $45 |
| Merck | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Circassia Inc. | 1 | $16 |
| Veran Medical Technologies, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Amgen | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,862 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,263 | $1,045,661 |
| OfevNintedanib Esylate | 62 | $733,721 |
| NucalaMepolizumab | 81 | $281,942 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 198 | $169,596 |
| Dupixent PenDupilumab | 25 | $114,701 |
| Spiriva RespimatTiotropium Bromide | 136 | $101,119 |
| Breo ElliptaFluticasone/Vilanterol | 139 | $66,431 |
| TezspireTezepelumab-Ekko | 11 | $51,296 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $41,173 |
| Pirfenidone | 18 | $38,578 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $31,383 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 46 | $30,696 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 775 | $29,166 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $26,237 |
| Atrovent HfaIpratropium Bromide | 41 | $23,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $689 | $1,425,9511,541 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $308 | $906,708310 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $780 | $262,187317 claims |
| MerckDulera | $40 | $11,80528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Tyler
- Leon TungTyler$43K
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
- Carlo HatemEl Paso$1.6M
- Deepa GoturHouston$1.1M
- Matt KhoshnevisHouston$759K
- Sean GilbeyAustin$723K
- Rodeo AbrencilloHouston$616K
- Jeffrey DellavolpeFort Sam Houston$466K
- Steven DavidoffPlano$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.